Apexigen today announced a collaboration with Columbia University Irving Medical Center on a new Phase 2 study for its lead immuno-oncology (I-O) therapeutic APX005M, a monoclonal antibody targeting CD40, in combination with doxorubicin and olaratumab in patients with advanced sarcomas. The trial is being funded by Apexigen and is being conducted by researchers at Columbia University Irving Medical Center. “We are excited to collaborate on this important new study,” said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. “We believe that combining APX005M with the standard of care could benefit many cancer patients. In conducting this trial, we hope that we may advance better I-O treatment options for patients with sarcomas.”